Table 1.

Effects of cannabidiol (CBD) on locomotor alterations induced by experimental models reproducing diseases.

Species	Experimental Model or Disease	CBD Administration	Locomotor Activity	Reference
Rat	Hypolocomotion associated with Parkinson’s disease induced by s.c. reserpine 1 mg/kg	Single i.p. 0.5 or 5 mg/kg or vehicle	Reduction of catalepsy and tardive dyskinesia	[47]
Mouse	Hepatic encephalopathy induced by bile-duct ligation	Daily i.p. 5 mg/kg or vehicle for four weeks	Reduction of hypolocomotion	[49]
Fmr1 knock out mouse	Fragile X syndrome	Single i.p. 5 or 20 mg/kg or vehicle	No effect on hyperlocomotion	[56]
APP/PS1 Mouse	Alzheimer disease	Daily i.p. 5 mg/kg or vehicle for 3 weeks before the beginning of experiments and during behavioral test assessment	No effect on locomotor activity	[59]
Mouse	Depressive and anxious-like behavior induced by LPS	Single i.p. 30 mg/kg or vehicle 30 min before LPS	No effect on changes in time spent in the center or distance travelled induced by LPS	[60]

i.p. = intraperitoneal; s.c. = subcutaneous; LPS = lipopolysaccharide.